GAIA is a research-based public health company. They have an in-house software technology platform called Broca 4.0 Their most popular Broca program is deprexis, a CE-certified online treatment program for individualized, interactive depression treatment. It has proven to be effective in 5 randomized controlled trials (RCTs) as well as in real-life clinical settings as of 2016. Their current R&D pipeline with 7,000 patients in clinical trials covers a wide range of phase II and phase III next generation mHealth programmes, for conditions such as borderline personality disorder (priovi), generalized anxiety disorder / panic disorder / social phobia (velibra), fatigue in multiple sclerosis (elevida), or compliance support (covivio), among others.